Author: Janice Oh, Hsueh-Ling; Ken-En Gan, Samuel; Bertoletti, Antonio; Tan, Yee-Joo
                    Title: Understanding the T cell immune response in SARS coronavirus infection  Document date: 2012_9_5
                    ID: 5uoepd0r_7
                    
                    Snippet: Animal studies using mice primed intramuscularly with S DNA vaccine and boosted with subcutaneous HLA-A*02:01 restricted peptides 25 or with the S DNA vaccine alone 26 elicited antigen-specific CD8 1 T cell responses. In fact, one recent study showed that primeboost immunization of transgenic mice with 5 of the HLA-A*02:01 S peptides together with CpG oligodeoxynucleotide (ODN) could significantly enhance the frequency of peptide-specific CD8 1 T.....
                    
                    
                    
                     
                    
                    
                    
                    
                        
                            
                                Document: Animal studies using mice primed intramuscularly with S DNA vaccine and boosted with subcutaneous HLA-A*02:01 restricted peptides 25 or with the S DNA vaccine alone 26 elicited antigen-specific CD8 1 T cell responses. In fact, one recent study showed that primeboost immunization of transgenic mice with 5 of the HLA-A*02:01 S peptides together with CpG oligodeoxynucleotide (ODN) could significantly enhance the frequency of peptide-specific CD8 1 T cells. 27 Taken together, the S protein is not only capable of inducing neutralizing antibodies but also contains several immunogenic T cell epitopes. Some of these epitopes found in either the S1 or S2 domain of the protein should therefore be considered during SARS-CoV vaccine development.
 
  Search related documents: 
                                Co phrase  search for related documents- Animal study and cell response: 1
  - Animal study and dna vaccine: 1, 2, 3, 4, 5, 6
  - Animal study and neutralize antibody: 1
  - Animal study and recent study: 1, 2, 3, 4, 5, 6, 7
  - Animal study and SARS CoV vaccine development: 1, 2, 3
  - Animal study and transgenic mouse: 1, 2, 3, 4, 5
  - Animal study and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
  - cell epitope and dna vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9
  - cell epitope and neutralize antibody: 1
  - cell epitope and recent study: 1
  - cell epitope and SARS CoV vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
  - cell epitope and transgenic mouse: 1, 2, 3
  - cell epitope and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70
  - cell response and dna vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44
  - cell response and neutralize antibody: 1
  - cell response and recent study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
  - cell response and SARS CoV vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
  - cell response and transgenic mouse: 1, 2, 3, 4, 5
  - cell response and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
  
 
                                Co phrase  search for related documents, hyperlinks ordered by date